Lineage Cell Therapeutics underwent corporate restructuring, name changes, and historical spin-offs over decades from its original foundational entities, meaning its historical initial public offering price varies depending on the specific corporate predecessor timeline. Over the years, the company transitioned through multiple equity recapitalizations and ticker symbol updates to reach its current public market structure.